Sage Journals: Discover world-class research

Abstract

Objective

Cardiovascular diseases (CVDs) remain a primary reason for death, and current thrombolytic agents face significant limitations due to side effects and high costs. Plant-derived alternatives, particularly from the Curcuma genus, show promise as safer and more accessible thrombolytic options. However, the thrombolytic potential of Curcuma wallichii specifically remains largely unexplored. The aim of this study is to evaluate the thrombolytic and anti-inflammatory potential of the chloroform fraction of Curcuma wallichii rhizomes (CFCWR) through in vitro models and in silico molecular docking with ADMET predictions.

Methods

The anti-inflammatory activity of the CFCWR was studied through the HRBC stabilization method and thrombolytic activity was tested using the clot-lysis assay. Phytochemicals were detected using GC-MS and the compounds were subjected to in silico docking against tissue plasminogen activator (tPA), along with ADMET evaluation by computational methods.

Results

The CFCWR exhibited a wide range of membrane-stabilizing capabilities, showing 65.23 ± 0.02%stabilization at a concentration of 100 µg/mL. In contrast, it demonstrated clot lysis activity of 62.23 ± 1.56% at the same concentration in comparison with the standard streptokinase (89.14 ± 0.03%) in the in vitro thrombolytic model. GC-MS analysis identified more than 100 phytochemicals, among which 2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-7-oxo-7H-furo(3,2-g) exhibited the highest binding affinity (score -9.0 kcal/mol) toward the tPA protein. ADMET studies indicated that these compounds are non-carcinogenic, well-absorbed, and possess good oral bioavailability.

Conclusion

This study reports for the first time the thrombolytic activity of Curcuma wallichii and identifies bioactive phytochemicals with potential mechanistic interaction at the tPA active site. These findings justify further exploration of Curcuma wallichii as a potential therapeutic agent for cardiovascular diseases. Future studies should include in vivo evaluation of clot-dissolving efficacy and the isolation and characterization of bioactive compounds.

Keywords

thrombolytic streptokinase anti-inflammatory clot lysis

1. Introduction

Cardiovascular diseases (CVDs) persist as a major global health challenge contributing to an estimated 19.8 million deaths in 2022 and accounting for about one-third of total deaths worldwide.¹ The primary cause of death and long-term disability in many of these conditions is thrombosis, the formation of blood clots that block blood vessels.² While clot formation is a natural component of the body’s hemostatic process, excessive or dysregulated clotting can lead to severe vascular events like myocardial infarction, ischemic stroke, and venous thromboembolism.³ Therefore, the timely dissolution of these clots to restore blood flow is essential for reducing associated mortality and morbidity.

Inflammatory cytokines are now recognized as key mediators bridging inflammation and coagulation, often acting as primary triggers for coagulation activation.⁴ During systemic inflammation, increased levels of pro-inflammatory cytokines such as IL-6 and IL-1 shift the hemostatic balance toward coagulation by suppressing natural anticoagulant pathways and enhancing endothelial activation and tissue factor expression.⁵ These changes may potentiate thrombus formation and accelerate pathologies such as atherosclerosis, extensive tissue damage, and thrombosis. Persistent inflammation, regardless of its origin, can contribute to the development of serious complications, including portal hypertension, impaired hepatic perfusion, ischemic cardiac events or stroke, and tissue anoxia.⁶ Thrombosis is clinically associated with various disorders such as pancreatitis, cirrhosis, diverticulitis, and cholangiocarcinoma, and may also contribute to elevated mortality risk.⁷ Consequently, thrombosis represents a significant global health burden.

Existing anti-thrombotic therapies, such as antiplatelet agents and anticoagulants, are effective in preventing new clot formation but are not designed to break down existing clots.⁸ For this purpose, fibrinolytic agents like streptokinase and recombinant tissue plasminogen activators (rtPAs) are the current standard of care.⁹ Despite their life-saving capabilities, these agents come with significant drawbacks, notably a high risk of life-threatening bleeding complications, allergic reactions, and a short plasma half-life.^10-12 Moreover, their high cost and limited availability restrict their use in many resource-constrained settings, highlighting the critical need for safer, more affordable, and universally accessible thrombolytic drugs.

This urgent demand has driven a renewed interest in natural products, which are abundant sources of bioactive compounds with potential therapeutic properties against various human diseases. Natural products have become an alternative and supplementary treatment technique due to their diverse pharmacological and biological applications.^13-15 Traditional plant-based medicines serve as the primary health care source for nearly 80% of the world’s population, especially in developing countries.¹⁶ Medicinal plants are highly valued for their wide chemical diversity, bioavailability, and safety compared to synthetic drugs.¹⁷ In recent decades, numerous studies have reported the thrombolytic and anticoagulant properties of various phytochemicals, thereby fueling the search for plant-derived fibrinolytic agents.¹⁸ Several plants, including Allium sativum (garlic), Allium cepa (onion), Curcuma longa (turmeric), Ocimum sanctum, and Azadirachta indica have demonstrated promising clot-dissolving activities in preclinical studies.^19,20 Notably, garlic extracts and curcuminoids from turmeric have been associated with enhanced fibrinolysis, reduced platelet aggregation, and improved cardiovascular outcomes.²¹ These findings justify the systematic evaluation of unexplored medicinal plants for their thrombolytic potential.²²

The genus Curcuma (family Zingiberaceae) includes more than 133 species distributed all over the world, many of which are important in traditional medicine systems like Ayurveda, Unani, and Chinese medicine.²³ The genus has long been used as a medicinal agent in Islamic traditional medicine and other folk healing practices.²⁴ Traditionally, species of the Curcuma genus have been used in the treatment of various ailments, such as leprosy, cancer, hemorrhoids, asthma, inflammatory conditions, and wound healing.²⁵ However, phytochemical investigations of Curcuma species have identified a wide range of bioactive compounds such as curcuminoids, sesquiterpenes, and essential oils.²⁶ These compounds are known for their antioxidant, anti-inflammatory, liver-protective, anticancer, antimicrobial, and heart-protective properties.²⁷ Notably, Curcuma longa and Curcuma zedoaria have demonstrated fibrinolytic activity and the ability to reduce platelet aggregation, supporting their traditional use in treating circulatory problems.^28,29

Ethnopharmacologically, Curcuma wallichii (C. wallichii) has traditionally been used in the treatment of leucoderma, asthma, tumors, piles, rheumatism, and digestive disorders. Preliminary phytochemical analyses of C. wallichii rhizomes indicate the existence of carbohydrates, flavonoids, steroids, alkaloids, phenols, tannins, amino acids, terpenoids, and glycosides. The chloroform fraction of C. wallichii exhibited the highest antioxidant potential. In the DPPH free-radical scavenging assay, this fraction demonstrated a strong antioxidant effect, indicating potent radical-quenching activity.³⁰

However, despite a diverse array of bioactive compounds and an extensive history of traditional use, the cardiovascular and thrombolytic potential of C. wallichii remains largely unexplored for thrombolytic potential. Although related Curcuma species exhibit fibrinolytic activity. This study bridges this gap by integrating phytochemical profiling with in vitro and computational analyses, providing mechanistic insights into active compounds. In addition to experimental assays, computational approaches such as molecular docking and in silico ADMET analysis can predict interactions with key proteins and evaluate pharmacokinetic and safety properties.³¹ The molecular docking simulation technique has been evaluated for the exploration of the possible binding modes of receptors with selected ligands which reveals binding energetics and molecular interactions.³²

This study employed in vitro anti-inflammatory, clot lysis assays, GC-MS phytochemical profiling, molecular docking and in silico ADMET analysis to evaluate the thrombolytic potential of the chloroform fraction of C. wallichii rhizomes. The results are expected to provide insight into its potential as a safe and affordable thrombolytic agent and to aid the development of plant-based therapeutics for cardiovascular disorders.

2. Materials and Methods

2.1. Chemicals and Reagents

Analytical-grade methanol, chloroform, and other chemicals were sourced from Merck (India). Streptokinase (SK) was obtained from Beacon Pharmaceutical Ltd., Bangladesh, while acetylsalicylic acid was provided by ACME Laboratories Ltd., Bangladesh.

2.2. Collection, Preparation and Extraction of Plant Material

The C. wallichii rhizomes were collected from the National Herbarium, Bangladesh, in November 2022 and were authenticated by an expert taxonomist, where a voucher sample (accession no.: 104,530) was deposited. After washing and drying the plant materials were subjected to grinding. The extraction was performed according to the method described earlier by Hossain et al.²³ The coarse powder (1.7 kg) was kept in a light-protected bottle and soaked with 100% methanol (1 L × 5 times) at RT, with intermittent agitation. The mixture was initially filtered through cotton, followed by filtration using Whatman filter paper (11 μm). The crude methanolic extract (CME) was obtained (56 g) using a rotary evaporator under reduced pressure at 40°C. The CME (46 gm) was suspended in methanol (90%) 200 mL and then sequentially partitioned with n-hexane, chloroform and finally water using the modified Kupchan method.³³ This yielded the n-hexane fraction, chloroform fraction (CHCWR, 26.3 gm), and aqueous fraction.

2.3. In vitro Thrombolytic Assay

The study was performed following the method described by Prasad et al.³⁴ Initially, 0.5 mL of fresh blood samples was carefully transferred into pre-weighed microcentrifuge tubes obtained from the non-contraceptive and nonanticoagulated donors. Following incubation of the blood at 37°C for 45 minutes, serum was carefully removed without disturbing the clot, and the tubes were reweighed. A volume of 100 μL of the test sample, at concentrations of 6.25, 12.5, 25, 50, and 100 µg/mL, was added to each tube. In the assay, positive control tubes contained 100 µL of streptokinase (30,000 IU), whereas negative control tubes were filled with 100 µL of distilled water (DW). The tubes were incubated at 37°C for 90 minutes, after which the supernatant was removed and the tubes were reweighed. Finally, the percentage of clot lysis was estimated from the weight differences before and after lysis, and the experiment was performed in triplicate.

% o f c l o t l y s i s = \frac{W e i g h t o f r e l e a s e d c l o t}{C l o t w e i g h t} \times 100

2.4. Hypotonicity-Induced HRBC Membrane Stabilization Assay

This study was performed using the method described earlier by Shinde et al with slight modifications.³⁵ Initially, a 5 mL blood sample was obtained from a healthy donor, having refrained from NSAID intake for two weeks prior to donation. Then it was anticoagulated with dipotassium EDTA (final concentration: 2.2 mg/mL). The collected blood was centrifuged at 3,000 rpm for 10 min and washed repeatedly (three times) with an isotonic NaCl solution (154 mM) in 10 mM sodium phosphate buffer at pH 7.4. The cell pellet was finally resuspended in an equal volume of isotonic buffer. Subsequently, 0.5 mL of the resulting cell suspension was added to a mixture containing 5 mL of hypotonic solution (50 mM NaCl) and 100 µL of either the test sample or standard solution at concentrations of 6.25, 12.5, 25, 50, and 100 µg/mL in 10 mM sodium phosphate-buffered saline (pH 7.4). The control tube consisted of 0.5 mL of cell suspension, 5 mL of hypotonic solution, and 100 µL of distilled water (DW) in the same buffer. All reaction mixtures were incubated at room temperature for 10 minutes, followed by centrifugation at 3,000 × g for 10 minutes. After incubation and centrifugation, the absorbance of the supernatant was measured at 540 nm using a spectrophotometer (Centurion Scientific Ltd, UK). Acetyl salicylic acid served as the reference standard. The percentage of HRBC membrane stabilization was estimated utilizing the following formula:

% inhibition of hemolysis = 100 \times [1 - \frac{O D 2 - O D 1}{O D 3 - O D 1}]

where OD1 = test sample in isotonic solution, OD2 = test sample in hypotonic solution, OD3 = control sample in a hypotonic solution. All experiments were performed in triplicate.

2.5. GC-MS Analysis

The CFCWR was analyzed using gas chromatography-mass spectroscopy,³⁶ using a combined 8890 gas chromatography system (Agilent 19091S-433UI:2489267H, USA) coupled with an Agilent 7010B GC/TQ MS system, EI Ionization technique. An HP-5MS UI column (5% phenyl methyl siloxane, 30 m × 250 μm × 0.25 μm) was utilized for chromatographic separation. As the carrier gas, Helium was used. The flow rate was 1.0 mL/min, the injection volume was 1 μl, and a split ratio of 1:50. The injector temperature was precisely regulated at 250°C, with a maintained pressure of 11.653 psi. The thermal gradient program began at 120°C for 2 minutes. The system temperature was raised at 10°C/min until reaching 320°C, where it was held for 5 minutes. This resulted in a total elution time of 27 minutes. The mass spectrometric analysis was conducted under electron impact ionization at 70 eV, with a scanning mass range of 40–700 m/z. The acquired mass spectra were cross-referenced against a computer-assisted mass spectral database. The molecular fragmentation patterns of the separated constituents were analyzed and identified by comparing them with spectral chromatograms available in the 2020 edition of the National Institute of Standards and Technology (NIST) GC-MS library software. Compounds identified by GC-MS were selected for molecular docking based on their relative abundance in the chloroform extract and reported or predicted thrombolytic or cardiovascular activity, ensuring that the docking study focused on the most relevant bioactive phytochemicals.

2.6. Protein and Ligand Preparation

The RCSB Protein Data Bank (https://www.rcsb.org) provided the tPA 3D crystal structure (PDB ID: 1A5H). The selected 3D structures of ligands were obtained in SDF format from the PubChem database. These ligand structures were optimized through energy minimization and protonation using Avogadro software and then converted to PDB format for docking analysis.³⁷ For protein preparation, BIOVIA Discovery Studio Visualizer was used to clean the tPA structure by removing unnecessary chains, heteroatoms, and water molecules. Using the Open Babel software, the refined protein was then converted into PDBQT format.

2.7. Molecular Docking

AutoDock Vina from PyRx was employed to conduct all docking calculations on the active sites of the tPA protein, using the identified molecules from C. wallichii.³⁸ A grid box was selected to encompass the maximum surface area of the prepared protein. The grid center points were set to X = 28.6846, Y = 28.6031, Z = 9.2936, and the dimensions (Å) were X = 58.2800, Y = 76.9576, Z = 64.7700. The dimensions of the grid box were strategically defined to enclose the active site of the protein, specifically targeting its substrate-binding domain. Visualization was performed using BIOVIA Discovery Studio.³⁷

2.8. Pharmacokinetic Properties Analysis

Swiss ADME (https://www.swissadme.ch/index.php) and pkCSM-pharmacokinetics (https://biosig.unimelb.edu.au/pkcsm/prediction) were the online tools used for the prediction of molecular properties and pharmacokinetics (ADMET) of the molecules identified from C. wallichii.³⁹ During the generation phase, the Simplified Molecular Input Line Entry System (SMILES) was utilized for the selected molecules.⁴⁰

2.9. Statistical Analysis

Differences between streptokinase (SK) and plant extracts were analyzed using a paired Student’s t-test. Data are presented as mean ± standard deviation. All experiments were performed in triplicate. Comparisons between positive and negative controls were performed using one-way ANOVA, followed by Tukey’s post-hoc test for multiple comparisons. Normality and homogeneity of variance were assumed for parametric tests. Exact p-values are reported in the Results section, and significance was considered at p < 0.05. Statistical analyses were conducted with SPSS software (version 18.0, IBM, New York, USA).

3. Results

3.1. Membrane-Stabilization Test

Different concentrations of CFCWR demonstrated significant protective effects against hypotonicity-induced lysis of human erythrocyte membranes when compared to the standard acetylsalicylic acid (ASA) (Table 1). The membrane-stabilizing activity of CFCWR varied across concentrations, ranging from 8.16 ± 0.231% to 65.23 ± 0.256%. The highest concentration tested (100 µg/mL) exhibited the most pronounced protective effect, achieving a value of 65.23 ± 0.256%. In comparison, the standard ASA displayed a membrane-stabilizing capacity of 75.89 ± 0.01% at the same concentration, whereas the negative control showed minimal activity (1.67 ± 0.02%).

Table 1.

Membrane Stabilizing Capacity of CFCWR and Controls

Sample/Standard	Concentration (µg/mL)	% Membrane stabilization
Control	100	1.67 ± 0.02
ASA	6.25	9.17 ± 0.03
	12.5	17.34 ± 0.02
	25	26.47 ± 0.04
	50	48.39 ± 0.02
	100	75.89 ± 0.01
CFCWR	6.25	8.16 ± 0.231
	12.5	15.45 ± 0.331
	25	21.12 ± 0.287
	50	32.13 ± 0.322
	100	65.23 ± 0.256

3.2. In vitro Thrombolytic Assay

The concentration-dependent thrombolytic activity of the chloroform fraction of Curcuma wallichii rhizomes (CFCWR) was assessed using human clotted blood (Table 2). CFCWR induced clot lysis ranging from 7.16 ± 2.23% at 6.25 µg/mL to 62.23 ± 1.56% at 100 µg/mL. In comparison, the standard streptokinase (SK) produced 89.14 ± 0.03% clot lysis, whereas the negative control exhibited minimal activity (1.27 ± 0.02%). Although the highest values are relatively large, they are consistent across triplicate measurements, as reflected in the standard deviations, indicating reproducibility of the assay.

Table 2.

Clot Lysis Capacity of CFCWR and Controls

Sample/Standard	Concentration	% Clot lysis
Control	100 µg/mL	1.27 ± 0.02
SK	100 µL	89.14 ± 0.03
CFCWR	6.25 µg/mL	7.16 ± 2.23
	12.5 µg/mL	17.45 ± 3.33
	25 µg/mL	22.12 ± 2.87
	50 µg/mL	43.13 ± 1.32
	100 µg/mL	62.23 ± 1.56

3.3. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

The chromatographic spectra depicted in Figure 1 display well-defined peaks that represent the individual compounds detected, each corresponding to specific retention times and mass spectral patterns.

Figure 1.

GC-MS chromatogram of CFCWR

3.4. Molecular Docking and in Silico Analysis

Molecular docking analysis of selected bioactive compounds (Figure 2) identified from the GC–MS profile of CFCWR was performed against the human tissue plasminogen activator (tPA) (PDB ID: 1A5H). Among these, five molecules exhibited the most favorable binding affinities, with docking scores ranging from −7.8 to −9.0 kcal/mol (Table 3). The compound 2-(1-(β-D-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-7-oxo-7H-furo(3,2-g)chromene (CID: 91734609) demonstrated the strongest interaction (−9.0 kcal/mol), forming hydrogen bonds with HIS57 (3.8 Å) and GLN60 (4.86 Å) within the catalytic domain of tPA. Other key residues involved in the ligand–protein interactions included SER195, GLY216, TYR99, TRP215, and ALA190, which are essential for the catalytic function and substrate (fibrin/plasminogen) recognition of tPA. The next top-ranked ligands, 4-fluoro-2-trifluoromethylbenzoic acid, 2-(1-phenyleth-1-yl)-4-methoxyphenyl ester (CID: 91731575; −8.9 kcal/mol) and phthalic acid, 3,5-dimethylphenyl 4-methoxyphenyl ester (CID: 6425848; −8.8 kcal/mol), also formed stable hydrogen bonds with active-site residues, suggesting a strong potential to modulate the fibrinolytic activity of tPA (Figure 3).

Figure 2.

Structures of (A) 2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl)-2,3dihydro-7-oxo-7H-furo(3,2-g) chromene,(R)-, (B) Glutaricacid,3-chlorophenyl(2-naphthyl) methylester, (C) Phthalic acid,3,5-dimethylphenyl-methoxyphenylester, (D) 4-Fluoro-2-trifluoromethylbenzoicacid,2-(1phenyleth-1-yl)-4-methoxyphenylester, (E) N-(3-Acetylphenyl) benzeneethanamide

Table 3.

Docking Scores and Interacting Residues of the Top Five Phytocompounds From CFCWR Against tPA

Compound name	PubChem CID	Docking score kcal/mol	Residues involved in hydrogen bonds, distance (Å)	Interacting residues of target
Phthalic acid, 3,5-dimethylphenyl-4-methoxyphenylester	6425848	-8.8	GLY216, 3.78; SER195, 4.94	GLY216, SER195, ASP189, CYS191, LEU217
Glutaricacid,3-chlorophenyl(2-naphthyl) methylester	91717218	-7.8	TYR99, 5.97	TYR99, CYS22O, TRP215, TRP215
2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl)-2,3dihydro-7-oxo-7H-furo(3,2-g) chromene,(R)-	91734609	-9.0	HIS, 3.8; GLN60, 4.86	HIS57, GLN60, SER195, ALA190
4-Fluoro-2-trifluoromethyl benzoicacid,2 - (1phenyleth-1-yl)-4-methoxy phenylester	91731575	-8.9	TYR99, 5.74	TYR99, GLY216, TRP215, ALA190
N-(3-Acetylphenyl) benzeneethanamide	922311	-8.0	GLY216, 3.1	GLY216, TYR99, TRP215, ARG174

Figure 3.

2D and 3D representations of ligand interactions with the tPA active site (PDB: 1A5H). Panels (A–E) show 2D interaction diagrams of five selected ligands, where magenta circles indicate polar amino acids, green circles denote nonpolar amino acids, and orange circles represent positively charged residues. Panels (A–H) depict the corresponding 3D binding poses, with ligands shown in ball-and-stick representation. The protein surface is colored according to electrostatic potential: blue for positive, red for negative, and white for neutral regions. Mechanism of clot degradation by CFCWR

The physicochemical characteristics of the top five compounds were within the general range of drug-like molecules (Table 4). Molecular weights varied from 253.30 to 418.38 g/mol, while Log P values ranged between 1.88 and 3.65, suggesting moderate lipophilicity conducive to membrane permeability. All compounds exhibited a bioavailability score of 0.55, indicating acceptable oral bioavailability potential. The number of hydrogen bond donors (0-4) and acceptors (2-9) suggests potential for stable hydrogen bonding interactions. The moderate number of rotatable bonds (4–9) and suitable molar refractivity values (75.44–105.67) further imply favorable molecular flexibility and polarizability.

Table 4.

Molecular Properties of the Top Five Docked Phytocompounds From CFCWR

Molecular properties	Phthalic acid, 3,5-dimethylphenyl-4-methoxyphenylester	Glutaric acid,3-chlorophenyl (2-naphthyl) methylester	2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl)-2,3dihydro-7-oxo-7H-furo(3,2-g) chromene,(R)-	4-Fluoro-2-trifluoromethyl benzoicacid,2 - (1phenyleth-1-yl)-4-methoxy phenylester	N-(3-Acetylphenyl) benzene ethanamide
Molecular weight	376.40	382.84	408.40	418.38	253.30
Log P	3.65	3.53	1.88	3.65	2.18
Log S	-5.61	-5.31	-2.56	-6.54	-3.20
H-Bond Acceptor	5	4	9	7	2
H-Bond Donor	0	0	4	0	1
Molar Refractivity	105.67	105.46	99.83	103.55	75.44
Heavy Atoms	28	27	29	30	19
Rotatable Bonds	7	9	4	7	5
Fraction Csp3	0.13	0.18	0.55	0.17	0.12
Bioavailability Score	0.55	0.55	0.55	0.55	0.55

Drug-likeness evaluation showed that all five top compounds satisfied the majority of established filters (Table 5). The compounds complied with Ghose, Veber, Egan, and Muegge filters. Notably, 2-(1-(Beta-D-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-7-oxo-7H-furo(3,2-g) chromene fully complied with all major criteria (0 violations), highlighting it as a strong drug candidate. The other four compounds demonstrated only one or minor rule violations, remaining within acceptable ranges for lead optimization. All compounds were free from PAINS alerts, suggesting the absence of promiscuous or reactive moieties that could cause nonspecific binding.

Table 5.

Drug-Likeness Assessment of the Selected Five Phytocompounds From CFCWR

Drug like-nessproperties	Phthalic acid, 3,5-dimethylphenyl-4-methoxyphenylester	Glutaric acid,3-chlorophenyl (2-naphthyl) methylester	2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl)-2,3dihydro-7-oxo-7H-furo(3,2-g) chromene,(R)-	4-Fluoro-2-trifluoromethyl benzoicacid,2 -(1phenyleth-1-yl)-4-methoxy phenylester	N-(3-Acetylphenyl) benzene ethanamide
Lipinski	Yes; 1 violation	Yes; 1 violation	Yes; 0 violation	Yes; 1 violation	Yes; 0 violation
Ghose	Yes; 0 violation	Yes; 0 violation	Yes; 0 violation	Yes; 1 violation	Yes; 0 violation
Veber	Yes; 0 violation	Yes; 0 violation	Yes; 0 violation	Yes	Yes; 0 violation
Egan	Yes; 0 violation	Yes; 0 violation	Yes; 1 violation	Yes; 1 violation	Yes; 0 violation
Muegge	Yes; 1 violation	Yes; 1 violation	Yes; 0 violation	Yes; 1 violation	Yes; 0 violation
PAINS	0 alert	0 alert	0 alert	0 alert	0 alert

The in silico toxicity profiling revealed that all candidate molecules had low toxicity potential (Table 6). The predicted rat acute toxicity values ranged between 1.74-2.99, indicating a low risk of acute toxicity. AMES mutagenesis scores were minimal (≤0.03), confirming non-mutagenic behavior. Carcinogenicity probabilities were also low (0.08-0.47), and biodegradation indices indicated moderate environmental degradability, suggesting acceptable safety and biocompatibility. The compound 2-(1-(Beta-D-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-7-oxo-7H-furo(3,2-g)chromene again stood out, combining strong binding affinity with favorable toxicity and environmental profiles.

Table 6.

In silico Toxicity Prediction of the Selected Five Phytocompounds From CFCWR

Toxicity properties	Phthalic acid, 3,5-dimethylphenyl-4-methoxyphenylester	Glutaricacid,3-chlorophenyl (2-naphthyl) methylester	2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl)-2,3dihydro-7-oxo-7H-furo(3,2-g) chromene,(R)-	4-Fluoro-2-trifluoromethylbenzoicacid,2-(1phenyleth-1-yl)-4-methoxy phenylester	N-(3-Acetylphenyl) benzene ethanamide
Rat (Acute)	2.14	1.95	2.99	2.36	1.74
AMES Mutagenesis	0.001	0.024	0.03	0	0.032
Avian	0.035	0.097	0.021	0.062	0.061
Honeybee	0.474	0.28	0.644	0.658	0.351
T. Pyriformis	-5.17	-1.96	-22.23	-17.68	3.04
Carcinogenesis	0.132	0.471	0.111	0.081	0.427
Biodegradation	0.267	0.234	0.402	0.034	0.104

Pharmacokinetic analyses demonstrated high human intestinal absorption (HIA > 0.86) and good plasma protein binding (72–87%) for all five compounds (Table 7). All exhibited limited but measurable Caco-2 permeability, consistent with passive diffusion potential. The predicted blood-brain barrier (BBB) permeability varied among compounds, with the highest for phthalic acid,3,5-dimethylphenyl-4-methoxyphenyl ester (BBB: 0.999), suggesting possible CNS availability. Cytochrome P450 enzyme interaction profiles showed moderate potential as CYP3A4 substrates and inhibitors, which may influence metabolic stability. Clearance values ranged between 1.87–7.50 mL/min/kg, indicating satisfactory excretion rates.

Table 7.

Pharmacokinetic Parameters of the Top Five Phytocompounds From CFCWR

Pharmacokinetic properties		Phthalic acid,3,5 – dimethylphenyl – methoxy phenylester	Glutaricacid,3-chlorophenyl(2-naphthyl) methylester	2-(1-(Beta-d-glucopyranosyloxy)-1-methylethyl) -2,3dihydro-7-oxo -7H-furo(3,2-g) chromene,(R)-	4-Fluoro-2-trifluoromethylbenzoic acid,2-(1-phenyleth-1-yl)-4-methoxyphenylester	N-(3-Acetylphenyl) benzeneethanamide
Absorption	Caco-2 (logPaap)	-4.39	-5.04	-5.44	-4.81	-4.56
Absorption	Human Intestinal Absorption	0.979	0.997	0.868	0.995	0.996
Distribution	Blood Brain Barrier	0.999	1	0.084	1	0.991
Distribution	Plasma Protein Binding	79.25	80.76	76.5	87.42	72.84
Metabolism	CYP 3A4 Inhibitor	0.471	0.405	0.074	0.561	0.267
Metabolism	CYP 3A4 Substrate	0.665	0.523	0.209	0.476	0.382
Excretion	Clearance	1.87	6.57	4.83	7.5	4.02
Excretion	Half-Life	0.248	0.183	0.358	0.152	0.221

4. Discussion

Thrombosis represents a critical final common pathway leading to morbidity and mortality in several major cardiovascular disorders, including myocardial infarction and ischemic stroke. Despite considerable advances in elucidating the molecular mechanisms underlying thrombus formation and the complex pathophysiology of thrombosis, current pharmacological therapies for its prevention and management have largely remained unchanged for decades, with only incremental improvements achieved through the development of newer drug variants.⁴¹ Increasing evidence indicates that natural products possess significant antithrombotic potential, as demonstrated in both preclinical and clinical investigations. These bioactive compounds may offer promising preventive or adjunctive strategies to complement existing pharmacotherapies for thrombotic diseases. The membrane stabilization assay of erythrocytes is a widely accepted model for evaluating the anti-inflammatory potential of plant extracts.^42,43 Exposure of erythrocytes to harmful agents, such as hypotonic solutions,^44,45 induces membrane rupture leading to hemoglobin release and oxidative degradation.⁴² These phenomena result in the extravasation of serum proteins and fluids into surrounding tissues, thereby triggering an inflammatory response.⁴⁶ The compounds capable of stabilizing erythrocyte membranes hold promise as anti-inflammatory agents. In the present study, CFCWR exhibited considerable protection against hypotonic-induced hemolysis, demonstrating superior membrane stabilization compared to the standard ASA and the control.

Effective clot lysis is maintained through a dynamic balance between plasminogen activators promoting fibrin degradation and inhibitors such as PAI-1 that prevent overactive fibrinolysis.⁴⁷ It is the mechanism through which coagulation-induced fibrin clots are dissolved, ensuring proper blood flow.⁴⁸ Fibrinolysis is mainly driven by plasmin and modulated by activators such as tPA and urokinase (uPA). In this context, the CFCWR showed significant clot-dissolving potential, suggesting the presence of bioactive phytoconstituents capable of facilitating fibrinolysis or plasmin activation (Figure 4).

Figure 4.

Mechanism of clot degradation by CFCWR

While GC-MS identified numerous compounds, no isolation, quantification or bioactivity-guided fractionation was performed, molecular docking was therefore used as a preliminary mechanistic tool to identify potential bioactive compounds for future studies. The computational evaluation of CFCWR phytocompounds revealed promising thrombolytic potential through efficient binding to the tPA active site. 2-(1-(Beta-D-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-7-oxo-7H-furo(3,2-g)chromene, displayed the highest binding affinity (−9.0 kcal/mol), engaging catalytically relevant residues such as HIS57, SER195, and GLN60. These residues are well-known for their involvement in fibrinolytic mechanisms, suggesting that this compound could mimic or enhance natural thrombolytic processes by destabilizing fibrin networks.^49,50 However, these docking results represent predicted ligand–protein interactions and should be interpreted only as supportive computational evidence complementing the observed in vitro thrombolytic activity.

Comparative binding energies indicated that other compounds, particularly 4-fluoro-2-trifluoromethylbenzoic acid,2-(1-phenyleth-1-yl)-4-methoxyphenyl ester, and phthalic acid,3,5-dimethylphenyl-4-methoxyphenyl ester, also exhibit significant potential. Polar interactions, such as hydrogen bonding or dipole contacts with residues like Tyr99, Gly216, and Trp215, may further stabilize ligand binding in the fibrin binding pocket. In thrombin and related serine proteases, tryptophan residues (like Trp215) have been shown to contribute significantly to ligand binding and substrate recognition.⁵¹ Moreover, surface loop residues adjacent to active sites are known to modulate binding specificity through polar interactions in serine proteases.⁴⁹ These interactions are consistent with previous computational studies, where hydrophobic substitution improved ligand affinity toward tPA.

In terms of molecular characteristics, the selected top five candidates adhered closely to drug-likeness standards, with acceptable Log P and molecular weight values, minimal rule violations, and absence of PAINS alerts.⁵² Such profiles reinforce the notion that these compounds could possess both bioactive potency and pharmacokinetic suitability. The bioavailability scores (0.55) and rotatable bond counts (<10) are typical of molecules with good absorption and oral delivery prospects.^53,54

The predicted toxicity and ADMET results supported the safety of these phytochemicals. The low AMES mutagenicity and carcinogenicity probabilities, along with moderate clearance and non-inhibitory CYP3A4 profiles, indicate a low risk of adverse drug reactions. Moreover, the combination of strong human intestinal absorption and optimal plasma protein binding suggests efficient systemic exposure while minimizing toxicity accumulation.^51,55

While the present findings are promising, this study is limited to in vitro assays and computational analyses and lacks in vivo validation. Furthermore, the individual phytoconstituents identified were not isolated and experimentally verified for their specific thrombolytic activities. Therefore, further in vivo investigations and detailed mechanistic studies are necessary to confirm and substantiate the therapeutic potential of Curcuma wallichii.

The integrated molecular docking, pharmacokinetic, and toxicity results indicate that several phytocompounds from CFCWR can be promising lead compounds for further in vivo thrombolytic studies. The observed pharmacological potential of Curcuma wallichii supports its ethnomedicinal relevance and highlights the utility of in silico screening in identifying natural thrombolytic agents.

5. Conclusion

The present study demonstrates that the chloroform extract of Curcuma wallichii exhibits moderate thrombolytic activity in vitro. Molecular docking identified 2-(1-(β-D-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-7-oxo-7H-furo(3,2-g)chromene as the top bioactive compounds, showing favorable binding to key residues of tPA. The combined in vitro and in silico findings indicate that C. wallichii contains phytoconstituents with potential thrombolytic activity. Further studies, including compound isolation and mechanistic evaluation, are needed to better understand its biological effects and therapeutic relevance.

Footnotes

Acknowledgments

The authors thank the Department of Pharmacy, University of Rajshahi, Bangladesh, for providing facilities to carry out the research. Also, the authors would like to thank Dr. A. H. M. Mahbubur Rahman, a specialist taxonomist from Rajshahi University, for his assistance in authenticating the plant species.

ORCID iDs

Md. Abu Bakar Siddique Jami

Md. Sakib Al Hasan

A. H. M. Khurshid Alam

Ethical Considerations

The experimental procedure was approved both for animal and human models by the Institutional Animal, Medical Ethics, Biosafety and Biosecurity Committee of Rajshahi University, Bangladesh (Approval No. 218/320(41)/IAMEBBC/IBSc). All experimental procedures involving both animal and human subjects were carried out in accordance with relevant institutional, national, and international guidelines and regulations.

Consent to Participate

Informed consent was obtained from the healthy volunteers prior to human blood sample collection.

Author Contributions

Md Sabbir Hossain: Writing – Manuscript draft, Methodology, Investigation, Formal analysis, Data curation.

Sajib Ghosh: Software investigation.

Md. Abu Bakar Siddique Jami: Investigation, Software investigation, Writing – review & editing.

Md. Sakib Al Hasan: Data curation.

Joy Sarker: Writing – review & editing.

Md Golam Sadik: Writing – review & editing.

AHM Khurshid Alam: Writing –review & editing, Conceptualization, Visualization, Supervision, and Resources.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

All data generated or analyzed during this study are included in this published article.*

Appendix

References

Liu

Yang

Wang

. Interpretation of Annual Report on Cardiovascular Health and Diseases in China 2024. Biomed Environ Sci. 2025;38(8):893-917.

Mackman

. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.

Asada

Yamashita

Sato

Hatakeyama

. Pathophysiology of atherothrombosis: mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int. 2020;70(6):309-322.

Abdel-Bakky

Amin

Ewees

, et al. Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines. Viruses. 2022;14(2):228. doi:10.3390/v14020228.

Kohli

Shahzad

Jouppila

Holthöfer

Isermann

Lassila

. During systemic inflammation, elevated pro-inflammatory cytokines such as IL-6 and IL-1 shift the hemostatic balance toward coagulation by suppressing natural anticoagulant pathways and enhancing endothelial activation and tissue factor expression. Front Cardiovasc Med. 2022;9:866751. doi:10.3389/fcvm.2022.866751.

Jin

Liu

. Analysis of related factors of portal vein thrombosis in liver cirrhosis. BMC Gastroenterol. 2023;23(1):26. doi:10.1186/s12876-022-02632-z.

Conticchio

Maggialetti

Rescigno

, et al. Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report and Literature Review of 890 Patients Affected by Uncommon Primary Liver Tumor Presentation. J Clin Med. 2023;12(2):423. doi:10.3390/jcm12020423.

Patrono

Morais

Baigent

, et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760-1776.

Didehvar

Haghshenas

Yarmohammadi

Hajikarimloo

Ghafoury

. Tissue Plasminogen Activator as an Approved Strategy for Ischemic Stroke: A Review of tPA’s Structure, Mechanism of Action and the Novel Targeting Methods. J Mol Neurosci. 2025;75(4):152.

10.

Azarm

Sohrabi

Mohajer

Azarm

. Thrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature. J Res Med Sci Off J Isfahan Univ Med Sci. 2011;16(3):353-357.

11.

Petraglia

Latronico

Liuzzi

Fanigliulo

Crescenzi

Rossano

. Edible mushrooms as source of fibrin (ogen) olytic enzymes: Comparison between four cultivated species. Molecules. 2022;27(23):8145.

12.

Hacke

Kaste

Bluhmki

, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.

13.

Sharma

Gupta

Orfali

, et al. Evaluation of the antifungal, antioxidant, and anti-diabetic potential of the essential oil of Curcuma longa leaves from the North-Western Himalayas by in vitro and in silico analysis. Molecules. 2022;27(22):7664.

14.

Roni

MAH

Jami

MABS

Sultana

, et al. Traditional herbal interventions for premenstrual syndrome management: a comprehensive literature review. Int J Chem Biochem Sci. 2024;25(18):120-140. https://www.iscientific.org/wp-content/uploads/2024/03/10-IJBCS-24-25-18-010.pdf

15.

Roni

MAH

Jami

MABS

Hoque

, et al. Clinically proven natural products in aid of treating Parkinson’s disease: a comprehensive review. Curr Med. 2024;3(1):6. doi:10.1007/s44194-024-00033-w.

16.

Thalia

. Medicinal plants in global health: a comparative study of practices. Res Output J Public Heal Med. 2025;5(1):42-49.

17.

Newman

Cragg

. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285.

18.

Uddin

. Thrombolytic potentials of some medicinal plants used by the local people for cardiovascular diseases in Bangladesh. Bangladesh J Plant Taxon. Published online 2021.

19.

Khan

Habib

Rahman

Mannan

Sarker

MMI

Hawlader

. Thrombolytic potential of Ocimum sanctum L., Curcuma longa L., Azadirachta indica L. and Anacardium occidentale L. J basic Clin Pharm. 2011;2(3):125-127.

20.

Bedir

Almasri

Azar

Elnady

Al Raish

. Exploring the therapeutic potential of Allium cepa and Allium sativum extracts: Current strategies, emerging applications, and sustainability utilization. Biology (Basel). 2025;14(8):1088.

21.

Narsimha

Srividya

Swamy

Prasad

. Effect of Allium sativum (Garlic) extract on blood coagulation and fibrinolysis. Adv Pharmacol Clin Trials. 2017;2:1-3.

22.

Morris

Wang

Barnes

Bennett

Dawson-Hughes

Booth

. Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study. Neurology. 2018;90(3):e214-e222. doi:10.1212/WNL.0000000000004815.

23.

Hossain

Ashraful

ABM

Rahman

Rashid

Sadik

Alam

AHMK

. Anti-ROS and Anticancer Potential of Rhizomes and a Polyunsaturated Fatty Acid From Chloroform Fraction of Curcuma wallichii as a Bioactive Compound. Journal of Biochecmistry. 2025;9517484, 13 pages. doi:10.1155/jfbc/9517484.

24.

Akaberi

Sahebkar

Emami

. Turmeric and curcumin: from traditional to modern medicine. Stud Biomarkers New Targets Aging Res Iran Focus Turmeric Curcumin. 2021;1291:15-39.

25.

Baghel

Sharma

. Survey on fuzzy expert system. Int J Emerg Technol Adv Eng. 2013;3(12):230-233.

26.

Patel

Pandya

Desai

. In silico prediction of the mitigative potential of curcumin against deltamethrin toxicity. Int Assoc Biol Comput Dig. 2022;1(2):36-44.

27.

Obrzut

Gostyńska-Stawna

Kustrzyńska

Stawny

Krajka-Kuźniak

. Curcumin: A Natural Warrior Against Inflammatory Liver Diseases. Nutrients. 2025;17(8):1373. doi:10.3390/nu17081373.

28.

Sirisidthi

Kosai

Jiraungkoorskul

. Antithrombotic activity of turmeric (Curcuma longa): A review. Indian J Agric Res. 2016;50(2):101-106.

29.

Gharge

Hiremath

Kagawad

Jivaje

Palled

Suryawanshi

. Curcuma zedoaria Rosc (Zingiberaceae): a review on its chemical, pharmacological and biological activities. Futur J Pharm Sci. 2021;7(1):166.

30.

Hossain

Jami

MABS

Ashraful

ABM

, et al. Unveiling the anti-inflammatory activity of chloroform fraction of curcuma wallichii and its phytoconstituents by in vivo and in silico studies. Sci Rep. 2026;16(1):1762. doi:10.1038/s41598-025-28248-3.

31.

Ancuceanu

Lascu

Drăgănescu

Dinu

. In Silico ADME Methods Used in the Evaluation of Natural Products. Pharmaceutics. 2025;17(8):1002.

32.

Samova

Patel

Doctor

Pandya

Verma

. The effect of bisphenol A on testicular steroidogenesis and its amelioration by quercetin: an in vivo and in silico approach. Toxicol Res (Camb). 2018;7(1):22-31.

33.

Kupchan

Britton

Ziegler

Sigel

. Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysenterica. J Org Chem. 1973;38(1):178-179.

34.

Prasad

Kashyap

Deopujari

Purohit

Taori

Daginawala

. Development of an in vitro model to study clot lysis activity of thrombolytic drugs. Thromb J. 2006;4(1):14.

35.

Shinde

Phadke

Nair

Mungantiwar

Dikshit

Saraf

. Membrane stabilizing activity—a possible mechanism of action for the anti-inflammatory activity of Cedrus deodara wood oil. Fitoterapia. 1999;70(3):251-257.

36.

Chikowe

Bwaila

Ugbaja

Abouzied

. GC–MS analysis, molecular docking, and pharmacokinetic studies of Multidentia crassa extracts’ compounds for analgesic and anti-inflammatory activities in dentistry. Sci Rep. 2024;14(1):1-18. doi:10.1038/s41598-023-47737-x.

37.

Nag

Paul

Banerjee

Kundu

. In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. Comput Biol Med. 2021;137:104818. doi:10.1016/j.compbiomed.2021.104818.

38.

Kondapuram

Sarvagalla

Coumar

. Chapter 22 -Docking-Based Virtual Screening Using PyRx Tool: Autophagy Target Vps34 as a Case Study. In: Coumar MSBTMD for CADD. Academic Press; 2021:463-477. doi:10.1016/B978-0-12-822312-3.00019-9.

39.

Vellapandian

. In silico and pharmacokinetic assessment of echinocystic acid effectiveness in Alzheimer’s disease like pathology. Futur Sci OA. 2024;10(1):FSO904. doi:10.2144/fsoa-2023-0150.

40.

De Carlo

Ronchi

Piastra

Tosca

Magni

. Predicting ADMET Properties from Molecule SMILE: A Bottom-Up Approach Using Attention-Based Graph Neural Networks. Pharmaceutics. 2024;16(6):776. doi:10.3390/pharmaceutics16060776.

41.

Yamashita

Asada

. Underlying mechanisms of thrombus formation/growth in atherothrombosis and deep vein thrombosis. Pathol Int. 2023;73(2):65-80. doi:10.1111/pin.13305.

42.

Debnath

Das

Islam

Hassan

Uddin

SMG

. Membrane stabilization–A possible mechanism of action for the anti-inflammatory activity of a Bangladeshi medicinal plant: Erioglossum rubiginosum (Bara Harina). Pharmacogn J. 2013;5(3):104-107.

43.

Sabalingam

. Journal of Drug Delivery and Therapeutics In-vitro approaches to evaluate the anti-inflammatory potential of phytochemicals. A Review. 2025;15(1):187-192.

44.

Anosike

Obidoa

Ezeanyika

LUS

. Membrane stabilization as a mechanism of the anti-inflammatory activity of methanol extract of garden egg (Solanum aethiopicum). DARU J Pharm Sci. 2012;20(1):76. doi:10.1186/2008-2231-20-76.

45.

Liu

Wang

, et al. Red blood cells-derived components as biomimetic functional materials: Matching versatile delivery strategies based on structure and function. Bioact Mater. 2025;47:481-501.

46.

Bekassy

Lopatko Fagerström

Bader

Karpman

. Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation. Nat Rev Immunol. 2022;22(7):411-428. doi:10.1038/s41577-021-00634-8.

47.

Rahman

Sultana

Bin Emran

, et al. Effects of organic extracts of six Bangladeshi plants on in vitro thrombolysis and cytotoxicity. BMC Complement Altern Med. 2013;13(1):25.

48.

Weisel

Litvinov

. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem. 2008;6(3):161-180. doi:10.2174/187152508784871963.

49.

Goettig

Brandstetter

Magdolen

. Surface loops of trypsin-like serine proteases as determinants of function. Biochimie. 2019;166:52-76. doi:10.1016/j.biochi.2019.09.004.

50.

Al-Amer

. The role of thrombin in haemostasis. Blood Coagul Fibrinolysis. 2022;33(3):145-148. https://journals.lww.com/bloodcoagulation/fulltext/2022/04000/the_role_of_thrombin_in_haemostasis.1.aspx

51.

Bell

Stevens

Jia

, et al. Fluorescence Properties and Functional Roles of Tryptophan Residues 60d, 96, 148, 207, and 215 of Thrombin. J Biol Chem. 2000;275(38):29513-29520. doi:10.1074/jbc.M001759200.

52.

Daina

Michielin

Zoete

. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717. doi:10.1038/srep42717.

53.

Halder

Elma

. In silico identification of novel chemical compounds with anti-TB potential for the inhibition of InhA and EthR from Mycobacterium tuberculosis. Preprint posted online December 6, 2020. doi:10.1101/2020.12.04.411967.

54.

Martin

. A Bioavailability Score. J Med Chem. 2005;48(9):3164-3170. doi:10.1021/jm0492002.

55.

Guan

Yang

Cai

, et al. ADMET-score– a comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm. 2019;10(1):148-157. doi:10.1039/C8MD00472B.

Evaluation of Membrane-Stabilizing and Clot-Lysing Activities of the Chloroform Fraction of Curcuma wallichii Rhizomes: An in vitro Model With Molecular Docking

Abstract

Objective

Methods

Results

Conclusion

Keywords

1. Introduction

2. Materials and Methods

2.1. Chemicals and Reagents

2.2. Collection, Preparation and Extraction of Plant Material

2.3. In vitro Thrombolytic Assay

2.4. Hypotonicity-Induced HRBC Membrane Stabilization Assay

2.5. GC-MS Analysis

2.6. Protein and Ligand Preparation

2.7. Molecular Docking

2.8. Pharmacokinetic Properties Analysis

2.9. Statistical Analysis

3. Results

3.1. Membrane-Stabilization Test

3.2. In vitro Thrombolytic Assay

3.3. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

3.4. Molecular Docking and in Silico Analysis

4. Discussion

5. Conclusion

Footnotes

Acknowledgments

ORCID iDs

Ethical Considerations

Consent to Participate

Author Contributions

Funding

Declaration of Conflicting Interests

Data Availability Statement

Appendix

References